Clinics and research in hepatology and gastroenterology · 2026
Risk factors for poor response to autoimmune hepatitis: A systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mo Wenhui, Li Luohong, Dong Yongqi, Wang Yi, Shen Yi, Yang Fan, Wang Xianglin, Fan Xiaoli, Liu Honglan, Pang Hongquan
Аннотация
BACKGROUND: Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease and its prognosis is closely related to treatment response. This meta-analysis aimed to identify baseline predictors of treatment response in AIH.
METHODS: PubMed, Embase, Ovid MEDLINE, and the Cochrane Library were searched from inception to August 24, 2025. Study quality was assessed independently by two reviewers using the Newcastle-Ottawa Scale. Standardized mean differences (SMDs), odds ratios (ORs), and 95% confidence intervals (CIs) were pooled using random-effects models. Subgroup analyses, sensitivity analysis and evidence certainty assessment were also performed.
RESULTS: Forty-eight studies were included. Favorable treatment response was associated with older age (SMD: 0.41, 95% CI: 0.23-0.58), lower immunoglobulin G (IgG) levels (SMD: -0.71, 95% CI: -1.04 to -0.37), higher platelet count (SMD: 0.28, 95% CI: 0.03-0.54), mild fibrosis (OR: 0.15, 95% CI: 0.07-0.35), and rosette formation (OR: 0.21, 95% CI: 0.07-0.67). Poor treatment response was associated with smooth muscle antibodies (SMA) (OR: 1.42, 95% CI: 1.10-1.84) and baseline cirrhosis (OR: 2.61, 95% CI: 1.69-4.02).
CONCLUSION: Age, platelet count, IgG level, SMA, mild liver fibrosis, rosettes, and cirrhosis were associated with treatment response in AIH and may help inform risk stratification. REGISTRY AND THE REGISTRATION NO.
OF STUDY: PROSPERO registration number CRD42024623543.
METHODS: PubMed, Embase, Ovid MEDLINE, and the Cochrane Library were searched from inception to August 24, 2025. Study quality was assessed independently by two reviewers using the Newcastle-Ottawa Scale. Standardized mean differences (SMDs), odds ratios (ORs), and 95% confidence intervals (CIs) were pooled using random-effects models. Subgroup analyses, sensitivity analysis and evidence certainty assessment were also performed.
RESULTS: Forty-eight studies were included. Favorable treatment response was associated with older age (SMD: 0.41, 95% CI: 0.23-0.58), lower immunoglobulin G (IgG) levels (SMD: -0.71, 95% CI: -1.04 to -0.37), higher platelet count (SMD: 0.28, 95% CI: 0.03-0.54), mild fibrosis (OR: 0.15, 95% CI: 0.07-0.35), and rosette formation (OR: 0.21, 95% CI: 0.07-0.67). Poor treatment response was associated with smooth muscle antibodies (SMA) (OR: 1.42, 95% CI: 1.10-1.84) and baseline cirrhosis (OR: 2.61, 95% CI: 1.69-4.02).
CONCLUSION: Age, platelet count, IgG level, SMA, mild liver fibrosis, rosettes, and cirrhosis were associated with treatment response in AIH and may help inform risk stratification. REGISTRY AND THE REGISTRATION NO.
OF STUDY: PROSPERO registration number CRD42024623543.